Latest News for: methicillin

Edit

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers And Barriers

MENA FN 23 Oct 2024
(MENAFN - GetNews) DelveInsight's,– Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2024 –report provides comprehensive insights about25+ companies and 27+ pipeline drugsin ... .
Edit

Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights | Clinical Trials, Latest Approvals, Therapies, Key Players | ...

GetNews 19 Jun 2024
"Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights" ... Methicillin-resistant Staphylococcus aureus Overview. Methicillin-resistant Staphylococcus aureus (MRSA) is among the most formidable modern pathogens.
Edit

POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS ...

My Horry News 21 May 2024
- OCM™ was significantly better than comparators at halting proliferation of MRSA and PA – ....
Edit

POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL

PR Newswire 20 May 2024
SARASOTA, Fla., May 20, 2024 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing ...
Edit

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review 2024: G7 & E7 Regional Insights, ...

Nasdaq Globe Newswire 29 Apr 2024
This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.
Edit

Methicillin-Resistant Staphylococcus Aureus Drugs Market Revenue To Reach USD 9 Billion By 2036, Says Research Nester

MENA FN 04 Mar 2024
(MENAFN - GlobeNewsWire - Nasdaq) Leading methicillin-resistant staphylococcus aureus drugs market players include BD (Becton, Dickinson, and Company), Melinta Therapeutics LLC, Dr. Reddy's ... .
Edit

OCM™ Wound Platform Demonstrates Antibacterial Activity in Porcine Wound Model, Significantly Reducing Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) Compared to Comparator and Control Groups

PR Newswire 08 Dec 2023
8, 2023 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCM™ alone ...
Edit

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry is anticipated to hit US$ 5.5 Billion by 2030, as indicated by FMI Analysis

Pharmiweb 13 Nov 2023
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry ... Staphylococcus aureus strains that have developed resistance to a variety of antibiotics are referred to as “methicillin-resistant staphylococcus aureus (MRSA) treatment industry”.
Edit

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Soars to US$ 5.5 Billion by 2030: FMI Analysis

Pharmiweb 08 Sep 2023
The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was estimated at US$ 3.8 billion in 2021 and is predicted to reach US$ 5.5 billion by 2030 with sales revenue expected to register CAGR of 4.3% over the forecast period.
Edit

Characterization of methicillin-resistant Staphylococcus aureus from ready-to-eat foods in China

Phys Dot Org 04 Sep 2023
Wei Wang et al, Antimicrobial Resistance, Virulence, and Genetic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered from Ready-to-Eat (RTE) Food in China.
Edit

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market is expected to reach US$ 5.5 Billion by 2030

Pharmiweb 09 Jun 2023
The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was estimated at US$ 3.8 billion in 2021 and is predicted to reach US$ 5.5 billion by 2030, according to a new market analysis conducted by Future Market Insights (FMI).
Edit

Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight

Nasdaq Globe Newswire 25 Jan 2023
Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus ... Methicillin-resistant ...

Most Viewed

×